Healthcare -
Biotechnology - NASDAQ - US
$ 0.884
-7.92 %
$ 4.8 M
Market Cap
-0.11
P/E
1. INTRINSIC VALUE
Balance Sheet
Dermata Therapeutics, Inc.
| Current Assets | 3.16 B |
| Cash & Short-Term Investments | 3.16 B |
| Receivables | 0 |
| Other Current Assets | 0 |
| Non-Current Assets | 0 |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 1.97 M |
| Accounts Payable | 808 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 1.16 M |
| Non-Current Liabilities | 1.16 B |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 1.16 B |
EFFICIENCY
Earnings Waterfall
Dermata Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 12.5 B |
| Operating Income | -12.5 B |
| Other Expenses | -226 M |
| Net Income | -12.3 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Dermata Therapeutics, Inc.
| Net Income | -12.3 B |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 658 M |
| Change in Working Capital | 467 K |
| Others | 467 M |
| Free Cash Flow | -11.2 B |
Wall Street Analysts Price Targets
Dermata Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for DRMA of $6 , with forecasts ranging from
a
low of
$6 to a high of $6 .
DRMA Lowest Price Target
Wall Street Target
6 USD
578.73%
DRMA Average Price Target
Wall Street Target
6 USD
578.73%
DRMA Highest Price Target
Wall Street Target
6 USD
578.73%
4. DIVIDEND
ANALYSIS
DRMA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Dermata Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company's common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024 (with respect to 3,825,138 warrants) and May 2024 (with respect to 1,009,332 warrants), at a reduced exercise price of $1.284 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File Nos.
accessnewswire.com
- 3 weeks ago
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne
Dermata Therapeutics, Inc. DRMA stock is trading higher on Thursday.
benzinga.com
- 3 weeks ago
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne - - Over 30 million acne patients seek treatment in the U.S. each year - SAN DIEGO , March 26, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. XYNGARITM also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.
prnewswire.com
- 3 weeks ago
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics (recently merged with Crown Laboratories) to study DMT410 for the treatment of axillary hyperhidrosis - - Raised $2.55 million in gross proceeds from a private placement financing in January 2025, including participation from Dermata's Chief Executive Officer, Chief Financial Officer, and certain members of the Company's board of directors - SAN DIEGO, CA / ACCESS Newswire / March 17, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today highlighted recent corporate progress and reported financial results for the year ended December 31, 2024. "I am very proud of what our team has accomplished this year, and we are excited to unblind the topline data from our XYNGARI™ Phase 3 STAR-1 trial in the coming weeks," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer.
accessnewswire.com
- 1 month ago
Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America - SAN DIEGO , March 4, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the last patient has completed their last visit in the Company's first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The Company remains on track to announce topline data by the end of March 2025.
prnewswire.com
- 1 month ago
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis - - The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis - SAN DIEGO, CA / ACCESS Newswire / February 25, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced the Australian Patent Office has accepted its patent application for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled "Compositions for the treatment of skin conditions," (Australian Patent Application No.
accessnewswire.com
- 1 month ago
Dermata to Present on BioPub on January 31, 2025
- Dermata's Chief Executive Officer and Chief Development Officer will provide a corporate update and answer live questions from the biotech investment community - SAN DIEGO, CA / ACCESS Newswire / January 29, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be featured as the presenting company on BioPub on January 31, 2025, at 12:00PM ET. This live, interactive, online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Gerry Proehl, and Chief Development Officer, Chris Nardo, Ph.D.
accessnewswire.com
- 2 months ago
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ clinical trial in March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy - SAN DIEGO, CA / ACCESS Newswire / January 28, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced issuance by the United States Patent and Trademark Office of a new patent for its XYNGARI™ product candidate for the treatment of acne. The issued patent, entitled "Compositions and methods for the treatment of skin conditions" (U.S. Patent No.
accessnewswire.com
- 2 months ago
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESS Newswire / January 23, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 2,007,880 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 2,007,880 shares of common stock at a purchase price of $1.27 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrant priced at-the-market under the rules of the Nasdaq Stock Market. The gross proceeds from the offering were approximately $2.55 million, prior to deducting placement agent's fees and other offering expenses payable by the Company.
accessnewswire.com
- 2 months ago
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,007,880 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 2,007,880 shares of common stock at a purchase price of $1.27 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrant in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The warrants will have an exercise price of $1.27 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants and will expire five years from the effective date of stockholder approval.
accessnewswire.com
- 2 months ago
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIRE / December 16, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that it received approval from U.S. Food and Drug Administration (FDA) of the proprietary name, Xyngari (pronounced zin-gar-ee) (formerly DMT310), for its Phase 3 clinical drug candidate in acne. The proprietary name, Xyngari, is approved pending the successful submission and acceptance of a new drug application (NDA).
accesswire.com
- 4 months ago
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne - - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 study for the treatment of acne and expects to announce topline results in March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy - SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced receipt of a notice of allowance from the United States Patent and Trademark Office of a new patent for its DMT310 product candidate for the treatment of acne. The allowed patent application, entitled "Compositions and methods for the treatment of skin conditions" (U.S. Application No.
accesswire.com
- 4 months ago
8. Profile
Summary
Dermata Therapeutics, Inc. DRMA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 4.8 M
Dividend Yield
0.00%
Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Contact
3525 Del Mar Heights Road, San Diego, CA, 92130
https://www.dermatarx.com
IPO
Date
Aug. 13, 2021
Employees
8
Officers
Mr. Sean Proehl
Associate General Counsel
Mr. Gerald T. Proehl
Founder, President, Chief Executive Officer & Chairman
Dr. Maria Bedoya Toro Munera M.B.A., Ph.D.
Senior Vice President of Regulatory Affairs & Quality Assurance
Dr. Christopher J. Nardo M.P.H., Ph.D.
Senior Vice President & Chief Development Officer
Ms. Kyri K. Van Hoose CPA, M.B.A.
Senior Vice President & Chief Financial Officer
Mr. David F. Hale
Co-Founder & Lead Independent Director